Carbamylation-derived products: Bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis

Clinical Chemistry

Volumn 57, Issue 11, 2011, Pages 1499-1505

  Jaisson, Stéphane ^a,b   Pietrement, Christine ^a,b   Gillery, Philippe ^a,b  

^a AMERICAN MEMORIAL HOSPITAL   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYANIC ACID; HEMOGLOBIN A1C; HOMOCITRULLINE; ISOCYANATE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARBAMOYLATION; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DISEASE COURSE; HUMAN; LIQUID CHROMATOGRAPHY; PATHOPHYSIOLOGY; PROTEIN PROCESSING; REVIEW; TANDEM MASS SPECTROMETRY;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CYANATES; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS;

EID: 80055078220     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.163188     Document Type: Review

References (68)

1. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010;56:1401-12.
2. Baynes JW. The clinical chemome: a tool for the diagnosis and management of chronic disease. Clin Chem 2004;50:1116-7. (Pubitemid 38824220)
3. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009;16:113-8.
4. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
5. Goldin A, Beckman JA, Schmidt AM, Creager MA.Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605. (Pubitemid 44199649)
6. Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001;78:S102-7. (Pubitemid 32144080)
7. Shah SV, Apostolov EO, Ok E, Basnakian AG. Novel mechanisms in accelerated atherosclerosis in kidney disease. J Ren Nutr 2008;18:65-9. (Pubitemid 350251831)
8. Gonzalez P, Grisolia S. Carbamylation of glutamate dehydrogenase and other mitochondrial proteins by biosynthetic carbamyl phosphate. Physiol Chem Phys 1975;7:271-5.
9. Ramponi G, Leaver JL, Grisolia S. Homocitrulline formation following carbamylation of histones with carbamyl phosphate. FEBS Lett 1971;16:311-4.
10. Stark GR. Modification of proteins with cyanate. Methods Enzymol 1967;11:590-4.
11. IUPAC, Commission on Nomenclature of Organic Chemistry. Specific classes of compounds: R-5.7.8 amides, imides, and hydrazides. http://www. acdlabs.com/iupac/nomenclature/93/r93-543.htm (Accessed August 2011). See subsection "R- 5.7.8.1 monoacyl derivatives of ammonia (primary amides)." Website version is very similar to the published version: A guide to IUPAC nomenclature of organic compounds: recommendations 1993. Boston: Blackwell Scientific; 1993.
12. Stark GR, Stein WH, Moore S. Reactions of the cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 1960;235:3177-81.
13. Nilsson L, Lundquist P, Kagedal B, Larsson R. Plasma cyanate concentrations in chronic renal failure. Clin Chem 1996;42:482-3.
14. Koshiishi I, Imanari T. State analysis of endogenous cyanate ion in human plasma. J Pharmacobiodyn 1990;13:254-8. (Pubitemid 20195763)
15. Houston RG. Sickle cell anemia and dietary precursors of cyanate. Am J Clin Nutr 1973;26: 1261-4.
16. Slungaard A, Mahoney JR Jr. Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. Implications for cytotoxicity. J Biol Chem 1991;266:4903-10. (Pubitemid 21909440)
17. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-84.
18. Nalbandian RM, Nichols BM, Stehouwer EJ, Camp FR Jr. Urea, urease, cyanate, and the sickling of hemoglobin S. Clin Chem 1972;18:961-4.
19. Nigen AM, Njikam N, Lee CK, Manning JM. Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains. J Biol Chem 1974;249:6611-6.
20. Nicholson DH, Harkness DR, Benson WE, Peterson CM. Cyanate-induced cataracts in patients with sickle-cell hemoglobinopathies. Arch Ophthalmol 1976;94:927-30.
21. Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev 2002;1: 465-79. (Pubitemid 38340335)
22. Balion CM, Draisey TF, Thibert RJ. Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 1998;53:488-95. (Pubitemid 28097868)
23. Oimomi M, Ishikawa K, Kawasaki T, Kubota S, Yoshimura Y, Baba S. Plasma carbamylated protein in renal failure. N Engl J Med 1983;308:655-6.
24. Kraus LM, Elberger AJ, Handorf CR, Pabst MJ, Kraus AP Jr. Urea-derived cyanate forms epsilonamino-carbamoyl-lysine (homocitrulline) in leukocyte proteins in patients with end-stage renal disease on peritoneal dialysis. J Lab Clin Med 1994;123:882-91.
25. Smith WG, Holden M, Benton M, Brown CB. Carbamylated haemoglobin in chronic renal failure. Clin Chim Acta 1988;178:297-303.
26. Kraus LM, Gaber L, Handorf CR, Marti HP, Kraus AP Jr. Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage. Swiss Med Wkly 2001;131:139-45. (Pubitemid 32246498)
27. Fazili KM, Mir MM, Qasim MA. Changes in protein stability upon chemical modification of lysine residues of bovine serum albumin by different reagents. Biochem Mol Biol Int 1993;31:807-16.
28. Beswick HT, Harding JJ. High-molecular-weight crystallin aggregate formation resulting from non-enzymic carbamylation of lens crystallins: relevance to cataract formation. Exp Eye Res 1987;45:569-78. (Pubitemid 18002996)
29. Jaisson S, Lorimier S, Ricard-Blum S, Sockalingum GD, Delevallee-Forte C, Kegelaer G, et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006;13:149-59. (Pubitemid 43255587)
30. Kuckel CL, Lubit BW, Lambooy PK, Farnsworth PN. Methylisocyanate and actin polymerization: the in vitro effects of carbamylation. Biochim Biophys Acta 1993;1162:143-8. (Pubitemid 23071412)
31. Cocco D, Rossi L, Barra D, Bossa F, Rotilio G. Carbamoylation of Cu,Zn-superoxide dismutase by cyanate. Role of lysines in the enzyme action. FEBS Lett 1982;150:303-6.
32. Van Lente F, McHugh A, Pippenger CE. Carbamylation of apo-aspartate aminotransferase: a possible mechanism for enzyme inactivation in uremic patients. Clin Chem 1986;32:2107-8.
33. Veronese FM, Piszkiewicz D, Smith EL. Inactivation of bovine glutamate dehydrogenase by carbamyl phosphate and cyanate. J Biol Chem 1972;247:754-9.
34. Oimomi M, Hatanaka H, Yoshimura Y, Yokono K, Baba S, Taketomi Y. Carbamylation of insulin and its biological activity. Nephron 1987;46:63-6. (Pubitemid 17057039)
35. Park KD, Mun KC, Chang EJ, Park SB, Kim HC. Inhibition of erythropoietin activity by cyanate. Scand J Urol Nephrol 2004;38:69-72.
36. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (Wash DC) 2004;305:239-42. (Pubitemid 38886736)
37. Garnotel R, Sabbah N, Jaisson S, Gillery P. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 2004;563:13-6. (Pubitemid 38471566)
38. Ha E, Bang JH, Son JN, Cho HC, Mun KC. Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma. Mol Med Report 2010;3:275-9.
39. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010;21:1852-7.
40. Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci (Lond) 2009;116:681-95.
41. Gross ML, Piecha G, Bierhaus A, Hanke W, Henle T, Schirmacher P, Ritz E. Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney. Am J Physiol Renal Physiol 2011;301:F476-85.
42. Shaykh M, Pegoraro AA, Mo W, Arruda JA, Dunea G, Singh AK. Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. J Lab Clin Med 1999;133:302-8. (Pubitemid 29112092)
43. Jaisson S, Larreta-Garde V, Bellon G, Hornebeck W, Garnotel R, Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007;26:190-6.
44. Jaisson S, Delevallee-Forte C, Toure F, Rieu P, Garnotel R, Gillery P. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007;581:1509 -13.
45. Kraus LM, Kraus AP Jr. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Wien Klin Wochenschr 1998;110:521-30. (Pubitemid 28407283)
46. Kraus LM, Traxinger R, Kraus AP. Uremia and insulin resistance: N-carbamoyl-asparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int 2004;65:881-7. (Pubitemid 38251063)
47. Horkko S, Huttunen K, Kervinen K, Kesaniemi YA. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 1994;24:105-13. (Pubitemid 24222972)
48. Roxborough HE, Young IS. Carbamylation of proteins and atherogenesis in renal failure. Med Hypotheses 1995;45:125-8.
49. Apostolov EO, Shah SV, Ray D, Basnakian AG. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009;29:1622-30.
50. Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007;27:826-32. (Pubitemid 46606713)
51. Apostolov EO, Basnakian AG, Yin X, Ok E, Shah SV. Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through MAPK pathway. Am J Physiol Heart Circ Physiol 2007;292:H1836-46. (Pubitemid 46578055)
52. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005;68:173-8. (Pubitemid 43181374)
53. Asci G, Basci A, Shah SV, Basnakian A, Toz H, Ozkahya M, et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008;13:480-6.
54. Carracedo J, Merino A, Briceno C, Soriano S, Buendia P, Calleros L, et al. Carbamylated lowdensity lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011;25:1314-22.
55. Holzer M, Gauster M, Pfeifer T, Wadsack C,Fauler G, Stiegler P, et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011;14:2337-46.
56. Farias G, Gonzalez-Billault C, Maccioni RB. Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Mol Cell Biochem 1997;168:59-66. (Pubitemid 27091056)
57. Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, Bokarewa M. Carbamylationdependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010;184:6882-90.
58. Fluckiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin carbamylation in uremia. N Engl J Med 1981;304:823-7. (Pubitemid 11147484)
59. Chachou A, Randoux C, Millart H, Chanard J, Gillery P. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med 2000;38:321-6.
60. Szymezak J, Lavalard E, Martin M, Leroy N, Gillery P. Carbamylated hemoglobin remains a critical issue in HbA1c measurements. Clin Chem Lab Med 2009;47:612-3.
61. Kwan JT, Carr EC, Bending MR, Barron JL. Determination of carbamylated hemoglobin by highperformance liquid chromatography. Clin Chem 1990;36:607-10.
62. Stim J, Shaykh M, Anwar F, Ansari A, Arruda JA, Dunea G. Factors determining hemoglobin carbamylation in renal failure. Kidney Int 1995;48:1605-10.
63. Davenport A, Jones SR, Goel S, Astley JP, Hartog M. Differentiation of acute from chronic renal impairment by detection of carbamylated haemoglobin. Lancet 1993;341:1614-7. (Pubitemid 23175244)
64. Wynckel A, Randoux C, Millart H, Desroches C, Gillery P, Canivet E, Chanard J. Kinetics of carbamylated haemoglobin in acute renal failure. Nephrol Dial Transplant 2000;15:1183-8. (Pubitemid 30487795)
65. Tarif N, Shaykh M, Stim J, Arruda JA, Dunea G. Carbamylated hemoglobin in hemodialysis patients. Am J Kidney Dis 1997;30:361-5. (Pubitemid 27391504)
66. Apostolov EO, Shah SV, Ok E, Basnakian AG. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005;51:719-28. (Pubitemid 40463923)
67. Kwan JT, Carr EC, Barron JL, Bending MR. Carbamylated haemoglobin-a retrospective index of time-averaged urea concentration. Nephrol Dial Transplant 1993;8:565-7. (Pubitemid 23199496)
68. Kraus LM, Jones MR, Kraus AP Jr. Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 1998;131:425-31. (Pubitemid 28259758)